In-Situ Cancer Vaccine: Phase I/IIb, Open-Label Study to Assess the Safety of AlloStim in Combination With Cryoablation as Third Line Therapy for Metastatic Colorectal Cancer
Phase of Trial: Phase I/II
Latest Information Update: 07 Nov 2016
At a glance
- Drugs T-cell vaccine-AlloStim (Primary) ; T-cell vaccine-AlloStim (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Immunovative Therapies
- 07 Jun 2017 Biomarkers information updated
- 07 Nov 2016 According to an Immunovative Therapies media release, first volunteers has been dosed with initial vaccine doses. Enrollment is expected to be completed by the end of July 2017.
- 19 Oct 2016 Planned End Date changed from 1 Nov 2018 to 1 Feb 2018.